FDA Warns that Vancomycin Eye Injections May Lead to Blindness

October 6, 2017: By Joan McKenna

1 Ophthalmic NewsVancomycin injections during eye surgery can lead to hemorrhagic occlusive retinal vasculitis (HORV), a rare, potentially blinding postoperative complication, the FDA warned Oct. 3 in a compounding risk alert to health care providers.

The agency said it received an adverse event report Aug. 14, 2017, for a patient who developed bilateral HORV after being administered injections of a compounded triamcinolone, moxifloxacin, and vancomycin (TMV) formulation in each eye at the conclusion of cataract surgeries performed two weeks apart. The TMV formulation was compounded by Imprimis Pharmaceuticals at its outsourcing facility in Ledgewood, New Jersey.

The FDA said symptoms of HORV include a delayed onset of sudden painless decreased vision, intraocular inflammation, intraretinal hemorrhage, retinal vasculitis, vascular occlusion, and retinal ischemia.

At the 2016 AAO meeting, Dean Eliott, MD, said HORV is suspected to be a rare type III hypersensitivity to vancomycin, but its exact cause and pathogenesis remain unproven.

The FDA said many ophthalmologists use intraocular vancomycin during cataract surgery to prevent postoperative endophthalmitis.

The agency said there is no US-approved vancomycin formulation for intraocular injection, and it is unaware of any adequately controlled studies demonstrating the safety and efficacy of vancomycin in preventing endophthalmitis.

The formulation is usually prepared at the surgical site or obtained in advance of surgery from a compounding pharmacy.

The agency concluded that prophylactic use of vancomycin, alone or in a compounded combination drugs, during cataract surgery is generally not recommended due to the risk of HORV.

The FDA said that, if vancomycin is administered to both eyes, patients with HORV likely will wind up legally blind.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022